This insulin-mediated CB1R stabilization provides a novel mechanistic link between hyperinsulinemia and the exacerbation of MASLD/MASH, suggesting that the hepatic insulin-ERK-CB1R axis may be a potential therapeutic target for metabolic liver diseases. The gene discussed is CNR1; the disease is metabolic dysfunction-associated steatotic liver disease.